Reduced expression of NQO1 is associated with resistance to geldanamycin-based HSP90i such as 17-AAG and 17-DMAG, but not to structurally unrelated HSP90i in glioblastoma, oesophageal and breast cancer cells [37–39]. Here, NQO1 is linked to glioblastoma.